Nutrition support and dietary interventions for patients with lung cancer: current insights by Kiss, Nicole
  
 
 
 
Kiss, Nicole 2016, Nutrition support and dietary interventions for patients with lung cancer: current insights, 
Lung cancer: targets and therapy, vol. 7, pp. 1-9. 
 
DOI: 10.2147/LCTT.S85347 
 
 
 
 
 
 
 
This is the published version. 
 
©2016, The Author 
 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Non-Commercial 
Licence 
 
 
 
 
 
 
 
 
 
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30093235 
 
 
 
 
 
© 2016 Kiss. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and 
incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Lung Cancer: Targets and Therapy 2016:7 1–9
Lung Cancer: Targets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/LCTT.S85347
Nutrition support and dietary interventions for 
patients with lung cancer: current insights
Nicole Kiss1,2
1Nutrition and Speech Pathology 
Department, Peter MacCallum Cancer 
Centre, east Melbourne, viC, Australia; 
2Department of Cancer experiences 
Research, Peter MacCallum Cancer 
Centre, east Melbourne, viC, Australia
Correspondence: Nicole Kiss 
Nutrition and Speech Pathology 
Department, Locked Bag 1,  
A’Beckett Street, east Melbourne,  
viC 3002, Australia 
Tel +61 3 9656 1002 
Fax +61 3 9656 1402 
email nicole.kiss@petermac.org
Abstract: Malnutrition and weight loss are prevalent in patients with lung cancer. The impact 
of malnutrition on patients with cancer, and specifically in patients with lung cancer, has been 
demonstrated in a large number of studies. Malnutrition has been shown to negatively affect 
treatment completion, survival, quality of life, physical function, and health care costs. Emerging 
evidence is providing some insight into which lung cancer patients are at higher nutritional 
risk. In lung cancer patients treated with radiotherapy, stage III or more disease, treatment with 
concurrent chemotherapy and the extent of radiotherapy delivered to the esophagus appear to 
confer a higher risk of weight loss during and post-treatment. Studies investigating nutrition 
interventions for lung cancer patients have examined intensive dietary counseling, supple-
mentation with fish oils, and interdisciplinary models of nutrition and exercise interventions 
and show promise for improved outcomes from these interventions. However, further research 
utilizing these interventions in large clinical trials is required to definitively establish effective 
interventions in this patient group.
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Introduction
Lung cancer is the most common cancer worldwide with an estimated global incidence 
in 2012 of 1.8 million new cases, representing 12.9% of all new cancers.1 Treatment for 
lung cancer may consist of surgery, chemotherapy or radiotherapy, or any combination 
of these modalities. The treatment modality or combination depends on the prognostic 
indicators of performance status, weight loss, and stage of disease. However, other 
factors such as age and medical comorbidities are also taken into consideration.2,3 
This review will discuss nutrition impact symptoms associated with lung cancer and 
its treatment, factors associated with malnutrition in lung cancer and the impact on 
treatment and patient outcomes, as well as review nutrition interventions used with 
lung cancer patients.
Symptoms that impact on nutrition
A systematic review of symptoms in adults with lung cancer found that fatigue, 
pain, loss of appetite, coughing, and insomnia were the most common symptoms 
patients presented with at diagnosis.4 In contrast, the most common symptoms 
experienced during chemotherapy treatment were nausea, vomiting, and hair loss, 
and during radiotherapy treatment were dysphagia and sore throat.4 Clinical practice 
guidelines for the prevention, diagnosis, and management of lung cancer patients 
report that anorexia, fatigue, and esophagitis are the acute toxicities associated 
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with thoracic radiotherapy.5 An acute toxicity scoring tool 
developed for use in patients being treated with radiotherapy 
for lung cancer includes dysphagia, nausea, vomiting, 
skin reactions, and fatigue as the side effects that should 
be assessed and monitored during treatment.6 Patients 
with lung cancer have been reported to experience more 
symptoms than patients with other cancer diagnoses, with 
the type and number of symptoms varying over the course 
of the illness trajectory.4 A recent cross-sectional study of 
450 patients with advanced stage non-small cell lung cancer 
(NSCLC) found 100% of patients experienced fatigue and 
97% experienced loss of appetite.7
Nutrition impact symptoms are symptoms which 
affect the ability to achieve adequate nutritional intake and 
increase the risk of developing malnutrition.8 Segura et al, 
found in their malnutrition prevalence study that the presence 
of two nutrition impact symptoms were associated with 
difficulties in food intake.9 A number of the symptoms and 
treatment toxicities reported to be experienced by patients 
with lung cancer include nutrition impact symptoms, specifi-
cally loss of appetite, nausea, vomiting, fatigue, dysphagia, 
and esophagitis, placing lung cancer patients at increased 
risk of malnutrition.
Prevalence of malnutrition  
in lung cancer
Oncology patients are one of the groups with the highest 
prevalence of malnutrition.10 In a cross-sectional survey 
of 3,122 adult patients in acute care wards, patients admit-
ted to oncology wards were 1.7 times more likely to be 
malnourished than other participants.11 Malnutrition rates in 
patients with lung cancer are particularly high (Table 1). In a 
prospective longitudinal study of the prevalence of malnutri-
tion in patients presenting to an Australian oncology clinic 
prior to chemotherapy or radiotherapy treatment, 69% of 
patients with lung cancer were malnourished, higher than 
patients with colorectal or head and neck cancer, 57% and 
45% respectively.12 Several other studies have confirmed high 
rates of malnutrition or significant weight loss in patients with 
lung cancer. Hébuterne et al, found an overall rate of 45% 
malnutrition in inpatients with lung cancer. In the same study, 
a sub-analysis found 73% of lung cancer patients with meta-
static disease were malnourished compared to 5% of those 
with localized disease.13 Using the patient generated subjec-
tive global assessment, a nutrition assessment tool, Segura 
et al, found that 56% of lung cancer patients with advanced 
stage disease had a score greater than nine, indicating a criti-
cal need for nutrition intervention.9 In a group of oncology 
patients presenting to European outpatient clinics the median 
weight loss among lung cancer patients was 6.5%, with 
34.5% reporting significant weight loss of more than 10%.14 
A prospective study designed to evaluate the nutritional 
status of 207 patients referred to an outpatient radiotherapy 
department demonstrated that 33% of lung cancer patients 
were malnourished prior to starting radiotherapy, increasing 
to 50% at the end of treatment.15 More recent studies in lung 
cancer patients receiving radiotherapy have found between 
22% to 31% of patients have 5% or more weight loss within 
90 days from the start of radiotherapy, with the median 
weight loss among these patients between 8% to 9%.16,17 
Table 1 Malnutrition point prevalence studies in oncology patients reporting malnutrition rates in lung cancer subgroups
Citation Population Setting Malnutrition assessment  
method
Prevalence in 
lung patients
Mariani  
et al14
Adult cancer outpatients at  
diagnosis or in various stages of  
treatment or follow-up, N=1,556 
n=229 (lung)
Outpatient cancer  
patients of 17 hospitals,  
universities or scientific  
institutions in italy
weight loss .10% of usual body  
weight
34.5%
Hébuterne  
et al13
Adult cancer inpatients, N=1,903 
n=247 (lung)
inpatient wards of  
154 public or private  
hospitals in France
BMi #18.5 kg/m2 (for aged 18–74)  
or BMi #21 kg/m2 (for patients  
aged over 75) and/or #10% loss of  
weight from beginning of disease
45%
Segura  
et al9
Adult patients with advanced cancer  
at diagnosis or in various stages of  
treatment or follow-up, N=781 
n=172 (lung)
inpatient, outpatient or  
home-based care patients 
within the Spanish  
National Health System
Patient generated subjective global  
assessment (PG-SGA) score .9
56.4%
Read  
et al12
Adult cancer patients at  
first presentation, prior to  
chemotherapy, N=141 
n=32 (lung)
Outpatient oncology  
clinic in two hospitals in  
Sydney (Australia)
PG-SGA category B or C 69%
Abbreviations: BMi, body mass index; PG-SGA, patient-generated subjective global assessment.
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Importantly, approximately half of these patients reached 
this degree of weight loss during the post-treatment period, 
between 3 to 6 weeks following completion of radiotherapy, 
highlighting the post-treatment period as an important time 
to be monitoring nutrition. These studies demonstrate that 
malnutrition is prevalent across the disease and treatment 
trajectory of patients with lung cancer.
Factors associated with weight loss
In clinical practice it is useful to understand any factors pres-
ent at diagnosis or during treatment that are associated with 
a higher risk of weight loss or developing malnutrition. This 
allows clinicians to ensure patients with a high risk diagno-
sis or a high risk treatment are identified and provided with 
appropriate support. In patients with head and neck cancer 
these factors are relatively well-known. Evidence based 
practice guidelines for the nutritional management of adults 
with head and neck cancer recommend that patients with T4 
or hypopharyngeal tumors undergoing concurrent chemora-
diotherapy should be considered for prophylactic placement 
of a percutaneous endoscopic gastrostomy tube due to the 
risk of weight loss and malnutrition associated with these 
diagnoses and treatment.18 The literature also suggests that 
all T3 and T4 head and neck tumors,19,20 all stages of tumors 
of the hypopharynx, oral cavity, oropharynx, and larynx,21 
high doses of radiotherapy to the pharyngeal constrictor 
muscles,22 nodal stage,23 combined chemoradiotherapy,24–26 
and pre-treatment weight loss26,27 are associated with weight 
loss, but the evidence for these factors is less consistent across 
studies. Factors associated with weight loss and malnutrition 
in patients with lung cancer are just beginning to become 
established.
A number of studies have investigated clinical and 
radiotherapy dosimetric factors associated with the develop-
ment of acute or late radiation-induced esophagitis in lung 
cancer patients.28–30 A systematic review of dose-volume 
parameters predictive of esophagitis in patients receiving 
thoracic radiotherapy found the parameters that were most 
consistently and strongly associated with development of 
esophagitis were mean esophageal dose, and the volume 
of the esophagus receiving a dose of 20 Gy, 30 Gy, 40 Gy, 
50 Gy, and 60 Gy.31 A more recent systematic review and 
meta-analysis investigated factors predictive of clinically sig-
nificant radiation-induced esophagitis in 1,082 patients from 
15 studies conducted in Europe, North America, Asia, and 
Australia. It was identified that, while on univariate analysis 
several factors are predictive of radiation-induced esophagitis 
including disease stage, N stage, poor performance status, and 
type of concurrent chemotherapy, on multivariate analysis the 
volume of the esophagus receiving 60 Gy alone emerged as 
the best predictor.32
Two recent studies have investigated factors associated 
with clinically significant weight loss in lung cancer patients 
receiving radiotherapy. In a retrospective cohort of 96 lung 
cancer patients treated with radiotherapy with or without 
concurrent chemotherapy 31% (n=30) of patients had 
clinically significant weight loss of 5% or greater within the 
90 days from commencement of radiotherapy. The factors 
determined to be associated with $5% weight loss were 
treatment with concurrent chemotherapy for both small cell 
lung cancer (SCLC) and NSCLC, and late stage disease 
in NSCLC only.16 A second study of 50 NSCLC patients 
treated with concurrent chemo-radiotherapy investigated 
radiotherapy dosimetric factors associated with $5% weight 
loss. Similar to the literature reporting associations between 
dosimetric factors and esophagitis, an association was found 
between clinically significant weight loss and the maximum 
dose to the esophagus, and the absolute esophageal length 
receiving doses of 40 Gy, 50 Gy, and 60 Gy.17 These studies 
have provided new insight into the lung cancer patients who 
are at higher risk of nutritional decline during radiotherapy 
treatment (Table 2).
Impact of weight loss  
and malnutrition
It is well established that malnutrition and weight loss have 
significant negative consequences on both patient centered 
and treatment outcomes. Multiple international evidence-
based guidelines contain statements regarding the negative 
impact of malnutrition on quality of life (QoL), functional 
status, survival, hospital length of stay, and health care 
costs.33–35 There are relatively few studies that have investi-
gated the impact of malnutrition specifically in patients with 
lung cancer, however, many studies have been undertaken in 
mixed cancer populations and therefore have direct relevance 
to lung cancer patients.
Table 2 Factors associated with higher nutritional risk in lung 
cancer patients receiving radiotherapy
Associations with clinically 
significant weight loss $5%
Associations with acute 
radiation-induced esophagitis
•  Concurrent chemotherapy
•  Disease stage iii or more
•  Maximum radiotherapy dose to  
the esophagus
•  Absolute esophageal length  
receiving doses of 40, 50, and 60 Gy
•  Mean esophageal dose
•  volume of the esophagus 
receiving 20, 30, 40, 50, and 
60 Gy
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Patient centered outcomes
Studies in mixed tumor groups which included lung cancer 
patients have demonstrated the impact of weight loss on 
QoL, finding significantly worse QoL in patients with weight 
loss.36,37 In 104 lung, breast, and ovarian cancer patients, 
Ovesen et al, found QoL prior to any treatment was rated 
worse in patients who had experienced more than 5% loss of 
weight over the previous 3 months (P,0.05).37 In a mixed 
group of 907 cancer patients Nourissat et al, found similar 
results by comparing patients with and without 10% loss of 
weight since the onset of their illness, and at varying stages 
of treatment. The authors found mean global QoL was sig-
nificantly poorer (P,0.001) in patients with weight loss.36 
A number of studies investigating QoL have also looked at 
associations between weight loss or malnutrition and func-
tional capacity using the functional sub-scales of the QoL 
questionnaires. The only one that included a large number 
of lung cancer patients (n=138) was the study by Nourissat 
et al.36 In this study, patients with greater than 10% weight 
loss had worse outcomes on the European Organization for 
Research and Treatment of Cancer Quality of Life Question-
naire (EORTC-C30) functional scales; physical functions 
(P,0.001); functional handicap (P,0.001); emotional func-
tions (P=0.004); cognitive functions (P,0.001), and social 
functions (P,0.001). Similar results have been observed in 
studies of head and neck cancer, gastrointestinal cancer, and 
mixed cancer populations.38–41
Patients with poor nutritional status may be more likely 
to develop treatment toxicities which can result in a reduced 
dose of treatment being delivered.42,43 The development of 
treatment toxicities in patients with and without malnutri-
tion or weight loss has also been studied using the symptom 
scales within QoL questionnaires. In addition, some studies 
have used toxicity scoring tools to determine differences. The 
results of studies investigating the impact of weight loss or 
malnutrition on treatment toxicities are less consistent than 
those for QoL and functional capacity. This may be due to 
the large range of toxicities that are assessed and the different 
methods used to assess them. Four such studies have been 
conducted in patients with lung cancer. Ross et al, assessed 
toxicity using the World Health Organization toxicity criteria 
in lung cancer patients undergoing chemotherapy treat-
ment with and without 10% weight loss.44 NSCLC patients 
with weight loss were significantly more likely to develop 
severe anemia (P=0.003) but this finding was not observed 
in SCLC or patients with mesothelioma. No differences 
were observed for any other toxicities. In a study of NSCLC 
patients undergoing chemotherapy, treatment toxicities were 
assessed using the National Cancer Institute Common Toxic-
ity Criteria for Adverse Events.45 When all toxicities were 
assessed, patients who were malnourished developed more 
toxicities than well-nourished patients (31 vs 22, P=0.02). 
In the study by Nourissat et al, described previously, all 
symptoms except insomnia in the EORTC-C30 symptom 
scale were significantly worse for patients with greater than 
10% weight loss.36 A retrospective study of 425 stage IIIB 
NSCLC patients receiving chemoradiotherapy found that 
patients who lost weight during treatment experienced sig-
nificantly more grade 3 hematological and non-hematological 
toxicities, including acute radiation-induced esophagitis, than 
patients who maintained or gained weight. In addition, the 
onset of acute radiation-induced esophagitis was significantly 
earlier (day 16 vs day 23 of radiotherapy, P=0.02) in weight 
losing patients.46
Numerous studies using the EORTC-C30 as a measure 
of QoL include a separate analysis of the fatigue symptom 
scale from this questionnaire. The results of these studies 
overwhelmingly support an association between fatigue and 
weight loss or malnutrition. Six of these studies, in head 
and neck or mixed cancer groups, report significantly worse 
fatigue in patients with weight loss36,38,39,41,47 or malnutrition.40 
In the study by Nourissat et al, mean fatigue score in patients 
with less than 10% weight loss was 36.6 compared to 55.4 in 
patients with greater than 10% weight loss (P,0.001).
The use of health care resources is an important outcome 
measure in the setting of rising health care costs and an 
aging population. Studies in cancer patients including heath 
care utilization as an outcome measure have usually focused 
on hospital admissions and length of stay. There is strong 
evidence that malnutrition affects health care utilization and 
costs. Only one study has investigated health care utilization 
specifically in lung cancer patients. The retrospective study by 
Topkan et al, of 425 stage IIIB NSCLC patients demonstrated 
a higher rate of hospitalization (11.3% vs 6.4%, P=0.01) in 
patients who lost weight during chemoradiotherapy compared 
to those who maintained or gained weight.46
Treatment outcomes
A number of studies across multiple cancer types have found 
associations between weight loss or malnutrition and poorer 
treatment outcomes. These associations were independent of 
disease stage and other known prognostic factors.43,44,48,49 The 
mechanism by which this might occur is not fully understood 
but it is suggested that patients with weight loss or malnutri-
tion may have a poorer immune response, and poorer lung 
and cardiac function.42,44
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A number of studies have shown a reduced ability to 
complete cancer treatment among malnourished patients. 
A retrospective cohort of lung cancer patients (n=780) 
undergoing chemotherapy treatment found less patients 
who had presented with weight loss completed three cycles 
of chemotherapy than those who presented without weight 
loss (67% vs 81%, P,0.001).44 When patients with NSCLC, 
SCLC, and mesothelioma were examined separately, this 
finding was confirmed in NSCLC patients (64% vs 78%, 
P=0.003) but not SCLC patients (77% vs 84%, P=0.1) or 
mesothelioma patients (53% vs 72%, P=0.05). When the 
authors looked at frequency of dose reductions or treatment 
delays between patients with and without weight loss no 
significant difference was found overall. However, more 
patients with weight loss experienced treatment delays in the 
sub-group with NSCLC (9% vs 4%, P=0.04). Similarly, in 
a study by Topkan et al, patients who lost weight were less 
able to tolerate full concurrent chemoradiotherapy treatment. 
While both weight losing and weight stable patients all com-
pleted the prescribed radiotherapy dose, more patients who 
lost weight required a chemotherapy dose reduction (23% vs 
11%, P=0.02) or cessation of the chemotherapy component of 
treatment (17% vs 6.9%, P=0.007).46 Studies in other patient 
groups show similar findings.50,51
In a study of lung cancer patients undergoing chemo-
therapy, Ross et al, assessed both objective response to 
treatment on computed tomography scan and symptomatic 
response to treatment defined as improvement in a symptom 
maintained for a minimum of 3 weeks.44 No significant dif-
ference was found between patients with and without weight 
loss in objective response to treatment for either NSCLC or 
SCLC, however, a trend toward a lower response rate was 
observed in mesothelioma patients with weight loss (P=0.05). 
In contrast, NSCLC and mesothelioma patients with weight 
loss had fewer symptomatic responses compared to those 
without weight loss (44% vs 60%, P=0.004; 33% vs 65%, 
P=0.03, respectively). However, there was no difference in 
symptomatic response in SCLC (52% vs 64%, P=0.06). 
Again, studies in other patient groups demonstrate similar 
findings.42,49
A landmark study by Dewys et al, established the prog-
nostic effect of weight loss, independent of performance 
status or extent of the tumor, in cancer patients undergoing 
12 different chemotherapy protocols.43 This was a large study 
of multiple tumor groups (n=3,047), which demonstrated 
across all 12 protocols that patients with weight loss had 
reduced survival with this difference being significant in 
nine of the 12 protocols. In the protocols treating SCLC and 
NSCLC, median survival was shorter in patients with weight 
loss compared to those without weight loss (27 vs 34 weeks, 
P,0.05; 14 vs 20 weeks, P,0.01, respectively). In addition 
there appeared to be a difference in median survival by degree 
of weight loss in the NSCLC protocol (17 weeks 0%–5%; 
13 weeks 5%–10%; 11 weeks 0 .10%, P,0.01). Ross et al, 
also determined weight loss to be an independent predictor of 
shorter overall survival in NSCLC (relative risk [RR] =1.33, 
P=0.009), SCLC (RR =1.5, P=0.003), and mesothelioma 
(RR =1.92, P=0.03) patients undergoing chemotherapy treat-
ment.44 These results are further supported by a study in stage 
III lung cancer patients undergoing chemoradiotherapy fol-
lowed by surgery.52 Patients who experienced greater than 5% 
weight loss during chemoradiotherapy had a shorter overall 
survival (hazard ratio [HR] 2.80, P=0.03). In the same study, 
patients who had a body mass index greater than 25 prior to 
treatment but lost greater than 5% weight during chemora-
diation, had a shorter overall and progression-free survival 
(HR 4.63, P=0.005; HR 6.03, P=0.007, respectively). Also 
in radiotherapy patients, Topkan et al, found better overall 
survival, progression-free survival, and distant metastasis 
free survival (all P,0.05) in stage IIIB NSCLC patients 
who maintained or gained weight during chemoradiotherapy 
compared to those who lost weight.46 In surgical lung cancer 
patients, impaired nutritional status appears to be associated 
with reduced long-term survival but not mortality in hospital 
following surgery. Studies have reported an independent 
association between nutritional impairment measured by 
body mass index, fat free mass index or weight loss and 
reduced long-term survival,53,54 but failed to find an associa-
tion between nutritional parameters and 30-day in-hospital 
mortality in surgical lung cancer patients.55
With a high prevalence of malnutrition among lung cancer 
patients and in the setting of strong evidence demonstrating 
poorer outcomes for malnourished patients, it is important 
to examine the most effective type of nutrition intervention 
to prevent or treat malnutrition in this population.
Nutrition interventions
Early research conducted during the 1980s on nutrition 
intervention in lung cancer focused on the effect of parenteral 
nutrition during chemotherapy and radiotherapy on treat-
ment outcomes and survival with mixed results.56–58 Several 
of these randomized controlled trials were underpowered 
to detect an effect.59 It is now standard clinical practice to 
reserve the use of parenteral nutrition for those patients 
with a non-functioning gastrointestinal tract,60 and there-
fore the results of these studies are now of limited interest. 
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More recent studies have focused on the effect of novel 
agents, such as omega-3 fatty acids, or dietary counseling 
in lung cancer patients.
Dietary counseling
Intensive, individualized dietary counseling or medical nutri-
tion therapy is the intervention which has been demonstrated 
to improve dietary intake, nutritional status, functional status, 
and QoL in head and neck and gastrointestinal cancer patients 
treated with radiotherapy.18,35,61 However, there have been 
limited high quality studies undertaken investigating this 
intervention in patients with lung cancer. A recent system-
atic review on nutrition interventions in lung cancer patients 
treated with radiotherapy and/or chemotherapy revealed only 
five studies have investigated either dietary counseling or oral 
supplements in this patient group over the past 30 years.62 
The systematic review found that simple dietary counseling 
improved energy and protein intake in lung cancer patients 
receiving chemotherapy but appeared to have no impact on 
other outcomes including weight, nutritional status, QoL, 
treatment response or survival. However, the studies in 
chemotherapy patients all had substantial limitations which 
may have precluded the ability to detect an impact on these 
outcomes. There was insufficient evidence found investigat-
ing dietary counseling or oral supplements in lung cancer 
patients receiving radiotherapy and therefore no conclusion 
could be drawn on the impact of this intervention. Of note, 
none of the studies had investigated intensive, individual-
ized dietary counseling. It has previously been reported that 
undertaking supportive care research in lung cancer patients 
poses challenges including low recruitment and high attri-
tion which may explain the paucity of studies in this area.63 
A recent pilot randomized trial has established the feasibility 
of investigating intensive, individualized dietary counseling 
in lung cancer patients receiving radiotherapy paving the 
way for future larger trials to determine the efficacy of this 
intervention in lung cancer patients. The pilot randomized 
trial demonstrated clinically important differences favoring 
the intervention for weight, fat-free mass, physical wellbeing, 
and functional wellbeing, however, these results require con-
firmation in a larger sample.64 There remains limited evidence 
regarding the efficacy of dietary counseling in lung cancer 
patients, however recent studies show promise and scope for 
further well-designed research in this area.
Omega-3 fatty acids
Patients with advanced lung cancer are reported to have 
a relatively high prevalence of cancer cachexia which 
is generally believed to be resistant to traditional forms 
of nutrition intervention such as dietary counseling.65,66 
 Therefore, nutrition intervention research in lung cancer 
patients has tended to focus on the use of novel agents such 
as omega-3 fatty acids as a treatment for cancer cachexia.67–69 
A 2013 systematic review of the effect of omega-3 fatty acids 
on clinical outcomes in patients with cancer found mixed 
results.70 The review showed omega-3 fatty acids to be a 
safe intervention with a positive effect on QoL and physi-
cal activity. However, the effect of omega-3 fatty acids on 
weight, fat-free mass, and performance status was deemed 
inconclusive, while no benefit for nutritional intake, appe-
tite or survival were found. There have been several studies 
investigating omega-3 fatty acids in lung cancer patients. 
In a large double blind randomized trial of 518 advanced 
lung and gastrointestinal cancer patients not receiving any 
anti-cancer treatment, no benefit on weight, fat-free mass, 
physical function, appetite or survival were found from 
supplementation with 2 g or 4 g doses of eicosapentanoic 
acid.71 Two smaller studies in lung cancer patients receiving 
active treatment have shown more positive results. In 40 lung 
cancer patients receiving first line chemotherapy treatment, 
Murphy et al, found those who were randomized to receive 
2.2 g of fish oil maintained overall weight and maintained or 
gained muscle mass, measured from computed tomography 
images, over the course of chemotherapy compared to those 
who received standard care.68 However, it should be noted the 
authors acknowledge the limitations of the open-label study 
design and the possibility the improvement in weight may 
have been in part due to the chemotherapy treatment itself. 
Another study in 40 stage III NSCLC patients receiving 
chemoradiation treatment showed that patients randomized 
to receive 2.9 g fish oil within an oral nutrition supple-
ment had better weight and fat-free mass maintenance and 
improved protein and energy intake than those who received 
an isocaloric control supplement.69 While there does appear 
to be some benefit to omega-3 fatty acid supplementation for 
lung cancer patients on treatment, larger studies are required 
to confirm these findings.
enteral nutrition
While there are no studies reporting specifically on the 
efficacy of enteral nutrition in lung cancer patients, some 
studies have used enteral nutrition as a component of nutri-
tion intervention with fish oil or dietary counseling, however 
the use of enteral nutrition in these studies was in a limited 
capacity.69,72 Enteral nutrition is used relatively infrequently 
in patients with lung cancer, with reports of as few as 12% of 
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patients commencing enteral nutrition.17 In clinical practice 
enteral nutrition is more likely to be provided to lung cancer 
patients treated with curative intent chemoradiation where 
esophagitis can manifest as an acute toxicity severely limit-
ing oral intake. Emerging knowledge of the factors placing 
lung cancer patients at higher risk of clinically significant 
weight loss may provide the impetus required to utilize 
enteral nutrition more frequently in lung cancer patients. 
Studies evaluating the efficacy of using enteral nutrition as a 
component of medical nutrition therapy in higher nutritional 
risk lung cancer patients are required.
Multidisciplinary
Systematic reviews indicate exercise interventions are asso-
ciated with improved exercise capacity, physical strength, 
functional performance, and some domains of QoL in 
patients with NSCLC.73,74 Early studies indicate that cancer 
prehabilitation programs, mostly with exercise interventions 
prior to treatment, may improve treatment tolerance and the 
ability to undergo curative intent treatment.73,75 Models of 
care involving multi-modal nutritional rehabilitation pro-
grams, including nutritional, physical, and physiological 
interventions following completion of cancer treatment, have 
demonstrated positive effects on physical activity levels, 
fatigue, symptoms, weight, and nutritional status. While no 
studies of multi-modal nutrition and exercise interventions 
have been completed specifically in lung cancer patients there 
have been a number of reports of successful outcomes from 
cancer nutrition rehabilitation programs accessed by patients 
from a broad range of tumor groups. An uncontrolled pro-
spective intervention study of 188 advanced cancer patients 
who attended a 10- to 12-week interdisciplinary program 
which provided nutritional counseling alongside an exercise 
program and dedicated symptom control demonstrated strong 
improvements in physical activity and fatigue, moderate 
improvements in 6-minute walk test, while 77% of patients 
maintained their weight.76 Within this program patients had 
access to a dietitian, physical therapist, occupational thera-
pist, physician, social worker, and clinical nurse specialist. 
A further study of 173 cancer patients attending a similar 
8-week interdisciplinary program, including access to the 
same health professionals, reports significant improvements 
in physical performance, nutrition, symptom severity, fatigue, 
and physical endurance.77 In light of the multidisciplinary 
nature of the clinical management of cancer patients, further 
high quality research is required to investigate the efficacy 
of multi-modal interventions involving nutritional, physical 
and psychological interventions.
Conclusion
Lung cancer patients experience a high symptom burden with 
many of these symptoms affecting nutritional intake and the 
development of malnutrition, with the potential to subsequently 
impact patient-related and treatment outcomes. Nutrition sup-
port and interventions are vital to optimize the wellbeing of 
lung cancer patients and maximize their ability to complete 
lengthy cancer treatments. Current research on nutrition inter-
ventions in lung cancer patients shows promise in a number 
of areas including intensive individualized dietary counseling, 
fish oil supplementation as well as multi-modal interventions 
encompassing both nutrition and exercise. Further good quality 
research and large clinical trials are needed to establish effec-
tive interventions in this patient group.
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